Biochem/physiol Actions

Reversible: no

Target IC₅₀: 1-2.1 µM against agonist-induced phospholipase C activation in human platelets and neutrophils; 800 nM and 500 nM, respectively, against ET-1 and parathyroid hormone-induced Ca2+ transients; 50 nM against human polymorphonuclear neutrophil adhesion

Product does not compete with ATP.

Primary TargetAgonist-induced phospholipase C activation

Cell permeable: yes

General description

A potent, selective, and cell-permeable inhibitor C-type phosphatidylinositol-specific phospholipases. Inhibits agonist-induced phospholipase C activation (IC₅₀ = 1-2.1 µM) in human platelets and neutrophils. Inhibits ET-1 and parathyroid hormone-induced Ca²⁺ transients (IC₅₀ = 800 nM and 500 nM, respectively). Also inhibits agonist-induced down-regulation of muscarinic receptors in SK-N-SH neuroblastoma cells. Acts as a potent inhibitor of human polymorphonuclear neutrophil adhesion on biological surfaces (IC₅₀ = 50 nM). Reported to abolish T lymphoma cell invasion into fibroblast monolayers.

A potent, selective, and cell-permeable inhibitor C-type phosphatidylinositol-specific phospholipases. Inhibits agonist-induced phospholipase C activation (IC₅₀ = 1-2.1 µM) in human platelets and neutrophils. Inhibits ET-1 and parathyroid hormone induced Ca2⁺ transients (IC₅₀ = 800 nM and 500 nM, respectively). Also inhibits agonist-induced down-regulation of muscarinic receptors in SK-N-SH neuroblastoma cells. Acts as a potent inhibitor of human polymorphonuclear neutrophil adhesion on biological surfaces (IC₅₀ = 50 nM). Abolishes T lymphoma cell invasion into fibroblast monolayers.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Stam, J.C., et al. 1998. EMBO J. 17, 4066.Smith, R.J., et al. 1996. J. Pharmacol. Exp. Ther.278, 320.Tatrai, A., et al. 1994. Biochim. Biophys. Acta 1224, 595.Wang, X.D., et al. 1994. Biochim. Biophys. Acta1223, 101.Bleasdale, J.E., and Fisher, S.K. 1993. Neuroprotocols: A Companion to Methods in Neurosci. 3, 125.Wu, H., et al. 1992. Biochemistry31, 3370.Yule, D.I., and Williams, J.A. 1992. J. Biol. Chem.267, 13830.Thompson, A.K., et al. 1991. J. Biol. Chem.266, 23856.

Packaging

5 mg in Plastic ampoule

Preparation Note

The use of anhydrous solvents is critical for the solubility of the compound; the presence of moisture in the solvent will lower the solubility of the compound.

Reconstitution

Unstable in DMSO and ethanol; reconstitute in anhydrous DMSO or ethanol just prior to use. Following reconstitution in anhydrous chloroform, aliquot into single use volumes, evaporate to dryness under a stream of nitrogen, and freeze (-20°C. Dried aliquots are stable for up to 6 months at -20°C. ); Reconstitute dried aliquots in anhydrous DMSO or anhydrous ethanol just prior to use.

Warning

Toxicity: Irritant (B)